EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review

Zachary Bloomgarden iD

Journal of Diabetes · 2026-07 · 18 (7)

DOI: 10.1111/1753-0407.70248 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Diabetes, online erschienen am 08.07.2026. Verfasst von Zachary Bloomgarden. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Incretins, Diabetes Mellitus, Type 2, Randomized Controlled Trials as Topic, Hypoglycemic Agents. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Incretin‐based therapies have transformed the management of obesity and type 2 diabetes (T2D). Pivotal randomized controlled trials (RCTs) report substantial weight loss and glycemic improvements; the extent to which these translate to clinical populations remains uncertain. Seven 2026‐published RCT meta‐analyses (comprising 127 RCTs and 58 976 participants) were compared with 26 real‐world studies identified through structured PubMed search. Primary outcomes were body weight loss and HbA1c reduction; secondary outcomes included major adverse cardiovascular events (MACE), neurological end‐points, and safety. The comparison is descriptive. For T2D, real‐world semaglutide achieved 4.7–10.5 kg weight loss (6–12 months) and 1.0–1.3 percentage‐point HbA1c reductions, lower than RCT meta‐analytic estimates (tirzepatide mean difference [MD] −9.55% vs. placebo). Without diabetes, real‐world persister analyses (SHAPE study: semaglutide −14.1%, tirzepatide −16.5%) approximated per‐protocol RCT estimates (semaglutide −14.9%, tirzepatide 15 mg −20.9%), whereas intention‐to‐treat real‐world estimates were substantially lower. Just 13% of semaglutide users reached 2.4 mg and 25.9% of tirzepatide users reached 15 mg. Real‐world cardiovascular data showed 20%–46% MACE reductions, broadly consistent with the RCT reduction. Differences between T2D and non‐T2D populations likely reflect channeling bias and differential follow‐up. Real‐world incretin‐based therapy effectiveness is broadly consistent with RCT efficacy when dose attainment is accounted for. High discontinuation rates (20%–50% within 1 year) and prior GLP‐1 RA exposure track with the observed efficacy gap. Clinicians can expect RCT‐level outcomes in patients who tolerate and persist with target doses. Head‐to‐head cardiovascular outcome trials comparing tirzepatide and semaglutide in non‐diabetic populations are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsDiabetes Mellitus, Type 2Randomized Controlled Trials as TopicHypoglycemic AgentsObesityHumansSemaglutideWeight LossGlucagon-Like PeptidesTirzepatide

Substanzen

IncretinsHypoglycemic AgentsSemaglutideGlucagon-Like PeptidesTirzepatide

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Zachary Bloomgarden

Zitieren

APA

Bloomgarden, Z. (2026). Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review. Journal of Diabetes, 18(7). https://doi.org/10.1111/1753-0407.70248

Vancouver

Bloomgarden Z. Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review. Journal of Diabetes. 2026;18(7). doi:10.1111/1753-0407.70248

BibTeX
@article{Bloomgarden2026,
  author = {Bloomgarden, Zachary},
  title = {Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review},
  journal = {Journal of Diabetes},
  year = {2026},
  volume = {18},
  number = {7},
  doi = {10.1111/1753-0407.70248}
}
Kostenlos starten →